BioGaia AB (publ) (BIOGY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 31.78 means the share price is 31.78 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.26B is the value of all shares combined. Beta 0.42: the stock has moved about 58% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBioGaia AB (publ) (BIOGY) trades at $12.45. BioGaia AB (publ) is a Swedish healthcare company specializing in the development, manufacture, and sale of probiotic products. Market cap: $1.26B, Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for BIOGY: BIOGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIOGY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BIOGY: 1/2 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
BioGaia AB (publ) (BIOGY) Healthcare & Pipeline Overview
BioGaia AB (publ) is a Swedish healthcare company focused on probiotic solutions for gut, oral, and immune health. With a global reach spanning Europe, Asia-Pacific, and the Americas, BioGaia differentiates itself through its specialized probiotic formulations and diverse product offerings across pediatric and adult health segments.
What Is the Investment Thesis for BIOGY?
BioGaia presents an investment case centered on its established position in the growing probiotic market. The company's consistent profitability, demonstrated by a 21.6% profit margin and a 73.4% gross margin, highlights its operational efficiency. A return on equity of 21.9% suggests effective utilization of shareholder equity. Growth catalysts include expanding its product lines and distribution networks, particularly in the Asia-Pacific region. Potential risks include increasing competition in the probiotic market and regulatory hurdles in new markets. The company's beta of 0.42 indicates lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
BIOGY Key Highlights
Market capitalization of $1.26B, reflecting investor confidence in BioGaia's market position and growth potential.
- Profit margin of 21.6%, indicating strong profitability and efficient cost management.
- Gross margin of 73.4%, showcasing the company's ability to maintain high pricing and manage production costs effectively.
- Return on equity of 21.9%, demonstrating efficient utilization of shareholder investments.
- Beta of 0.42, suggesting lower volatility compared to the broader market, potentially appealing to risk-averse investors.
Who Are BIOGY's Competitors?
BIOGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| DSM BNY Mellon Strategic Municipal Bond Fund, Inc. | $5.58 | -1.59% | $276M | — |
| CHR Cheer Holding, Inc. | $1.67 | -5.11% | $49.7M | 535-pillar |
| IFF International Flavors & Fragrances Inc. | $84.15 | -0.19% | $21.5B | 545-pillar |
| CRON Cronos Group Inc. | $3.16 | +0.16% | $1.18B | 905-pillar |
| HROW Harrow Health, Inc. | $36.58 | -2.58% | $1.36B | 529-signal |
| PAHC Phibro Animal Health Corporation | $36.58 | -0.60% | $1.48B | 725-pillar |
| AMPH Amphastar Pharmaceuticals, Inc. | $23.54 | +2.17% | $1.04B | 765-pillar |
| PCRX Pacira BioSciences, Inc. | $25.16 | -2.78% | $990M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BIOGY's Key Strengths?
Proprietary probiotic strains with clinical backing.
- Strong brand recognition in key markets.
- Established distribution partnerships.
- High gross and profit margins.
What Are BIOGY's Weaknesses?
Reliance on distribution partners.
- Limited direct sales channels.
- Potential for increased competition.
- Exposure to regulatory changes in different markets.
What Could Drive BIOGY Stock Higher?
Potential regulatory approvals for new probiotic formulations in key markets.
- Expansion of distribution network in the Asia-Pacific region.
- Increasing consumer awareness of the benefits of probiotics for overall health.
- Publication of new clinical studies supporting the efficacy of BioGaia's products.
- Strategic partnerships with healthcare providers to promote probiotic solutions.
What Are the Key Risks for BIOGY?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 31.78 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Increased competition from larger pharmaceutical companies entering the probiotic market.
- Changes in regulatory requirements for probiotic products.
- Negative publicity regarding the efficacy or safety of probiotics.
- Reliance on distribution partners for sales and marketing.
- Patent expirations on key probiotic strains.
What Are the Growth Opportunities for BIOGY?
- Expanding into new geographic markets, particularly in the Asia-Pacific region, represents a significant growth opportunity for BioGaia. The increasing awareness of gut health and the rising disposable incomes in countries like China and India create a favorable environment for probiotic products. Establishing strategic partnerships with local distributors and tailoring products to meet regional preferences can drive market penetration. This expansion could contribute significantly to revenue growth within the next 3-5 years.
- Developing new probiotic formulations targeting specific health conditions beyond gut health, such as immune function and mental well-being, offers substantial growth potential. Investing in research and development to identify novel probiotic strains and their health benefits can create a competitive edge. Collaborating with research institutions and healthcare professionals can accelerate the development and validation of new products. Successful product launches in these areas could generate significant revenue streams over the next 2-4 years.
- Increasing penetration in the adult health segment by promoting the benefits of probiotics for bone health and oral health can drive revenue growth. Targeted marketing campaigns and educational initiatives can raise awareness among adults about the role of probiotics in maintaining overall health. Expanding distribution channels to include pharmacies, health food stores, and online retailers can improve accessibility to BioGaia's products. This strategy can contribute to steady growth in the adult health segment over the next 1-3 years.
- Leveraging the 'Other' segment, which focuses on packaging solutions, to offer innovative and sustainable packaging options for probiotic products can enhance brand image and attract environmentally conscious consumers. Developing eco-friendly packaging materials and reducing the environmental footprint of BioGaia's products can differentiate the company from competitors. This initiative can contribute to brand loyalty and attract a growing segment of consumers who prioritize sustainability.
- Capitalizing on the growing trend of personalized nutrition by offering customized probiotic solutions based on individual needs and preferences represents a significant growth opportunity. Developing diagnostic tools to assess an individual's gut microbiome and recommend specific probiotic formulations can enhance the effectiveness of BioGaia's products. Partnering with healthcare professionals to provide personalized recommendations can build trust and credibility. This approach can drive premium pricing and increase customer loyalty.
What Are BIOGY's Competitive Advantages?
- Proprietary probiotic strains with clinically proven benefits.
- Established distribution network across multiple regions.
- Strong brand reputation and consumer trust.
- Focus on research and development of innovative probiotic solutions.
What Does BIOGY Do?
BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden. The company develops, manufactures, markets, and sells probiotic products. BioGaia's core business revolves around probiotics aimed at improving gut, oral, and immune health. The company operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers products like drops, oral rehydration solutions, and gut health tablets, along with cultures used in infant and milk formulas. The Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures for dairy products. The Other segment focuses on packaging solutions. BioGaia distributes its products through partnerships and its own channels, reaching markets in Europe, the Middle East, Africa, the United States, the Asia-Pacific region, Australia, and New Zealand. BioGaia has established itself as a key player in the probiotic market through its focus on research-backed formulations and diverse product applications.
What Products and Services Does BIOGY Offer?
- Develops probiotic products for gut health.
- Manufactures probiotic supplements and formulations.
- Markets probiotic products to consumers and healthcare professionals.
- Sells probiotic products through distribution partners.
- Offers probiotic solutions for oral health.
- Provides probiotic cultures for use in infant formula.
- Offers packaging solutions for probiotic products.
How Does BIOGY Make Money?
- Develops and patents probiotic strains.
- Manufactures and packages probiotic products.
- Distributes products through partners and direct channels.
- Generates revenue through product sales.
What Industry Does BIOGY Operate In?
BioGaia operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing consumer awareness of preventative healthcare and the benefits of probiotics. The global probiotic market is expected to continue expanding, fueled by research highlighting the gut microbiome's impact on overall health. BioGaia competes with other probiotic manufacturers, both large pharmaceutical companies and smaller specialized firms. The company's focus on research and development and its established distribution network provide a competitive advantage.
Who Are BIOGY's Key Customers?
- Infants and children needing gut health support.
- Adults seeking to improve gut, bone, or oral health.
- Manufacturers of infant formula and dairy products.
- Healthcare professionals recommending probiotic products.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 53 |
| 2026-08-26 | 53 |
| 2026-08-29 | 53 |
| 2026-09-01 | 53 |
| 2026-09-04 | 53 |
| 2026-09-07 | 53 |
| 2026-09-10 | 53 |
What changed?
The score has stayed at 53.
Over the same 18 days the stock moved +0.8%.
Company Profile
BioGaia AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Theresa Agnew. BIOGY has traded publicly since 2021.
BioGaia AB (publ) Financial Trajectory
BioGaia AB (publ) (BIOGY) reported $440.9M in revenue for Q2 FY2026, reflecting 18.3% growth compared to the prior quarter. The company recorded net income of $103.2M, with diluted EPS of $1.02. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BIOGY averaged $0.86 in diluted EPS.
How BioGaia AB (publ) Is Valued
BioGaia AB (publ) carries a market capitalization of $1.26B, placing it in the small-cap category.
Key Financial Metrics
Return on equity for BioGaia AB (publ) stands at 26.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.6%, showing how much profit it generates from its asset base. BIOGY trades at a trailing price-to-earnings ratio of 31.78, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.94 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
BioGaia AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 33.80 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
BioGaia AB (publ) has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.1% below estimates on average.
BIOGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary probiotic strains with clinical backing.
- Strong brand recognition in key markets.
- Established distribution partnerships.
- High gross and profit margins.
Bear Case
- Reliance on distribution partners.
- Limited direct sales channels.
- Potential for increased competition.
- Exposure to regulatory changes in different markets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | kr441M | kr103M | kr1.02 |
| Q1 FY2026 | kr373M | kr79M | kr0.78 |
| Q4 FY2025 | kr441M | kr99M | kr0.98 |
| Q3 FY2025 | kr322M | kr65M | kr0.64 |
Q2 FY2026 · filed 30 Jun 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Reported in SEK
BIOGY Latest News
-
BioGaia AB (publ) (BIOGY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 17, 2026
BIOGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIOGY.
Price Targets
Wall Street price target analysis for BIOGY.
BIOGY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIOGY; grades run from A+ (80-100) to F (below 30).
BioGaia AB (publ) ADR Information Unsponsored
BioGaia AB (publ) (BIOGY) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BIOG
BIOGY OTC Market Information
The OTC Other tier, where BioGaia AB (publ) trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial reporting requirements and may not meet minimum listing standards. This contrasts with exchanges like the NYSE or NASDAQ, which have stringent listing requirements, including minimum share prices, market capitalization, and financial reporting standards. Investing in OTC Other stocks carries significantly higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in BIOGY.
- Lower trading volume can lead to price volatility and difficulty in executing trades.
- The OTC Other tier has less regulatory oversight, increasing the risk of fraud or manipulation.
- Lack of analyst coverage can make it harder to assess the company's prospects.
- Delisting risk if the company fails to meet minimum listing requirements of other exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market share.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established operating history since 1990.
- Global presence with sales in multiple regions.
- Focus on research and development of probiotic solutions.
- Partnerships with established distributors.
- Positive customer reviews and testimonials (if available).
BIOGY Healthcare Stock FAQ
Is BIOGY a good stock?
Stock Expert AI does not rate BIOGY buy, sell or hold. BioGaia AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does BioGaia AB (publ) do?
BioGaia AB (publ) is a healthcare company specializing in the development, manufacture, and sale of probiotic products. Its core focus is on improving gut, oral, and immune health through probiotic solutions. The company operates through three segments: Pediatrics, Adult Health, and Other.
What do analysts say about BIOGY stock?
As of 2026-03-16, formal analyst ratings for BIOGY on the OTC market are limited due to the stock's trading venue.
What are the key factors to evaluate for BIOGY?
Evaluate BIOGY on fundamentals, analyst consensus, and risk factors. P/E: 31.78x vs the S&P 500's ~20-25x. BioGaia presents an investment case centered on its established position in the growing probiotic market. Not financial advice.
How frequently does BIOGY data refresh on this page?
BIOGY's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BIOGY's recent stock price performance?
BioGaia AB (publ) (BIOGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary probiotic strains with clinical backing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOGY overvalued or undervalued right now?
BioGaia AB (publ) (BIOGY) trades at 31.78x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BIOGY?
Yes, most major brokerages offer fractional shares of BioGaia AB (publ) (BIOGY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.